NewAmsterdam Pharma Company N.V.
corporate_fare Company Profile
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for NAMS at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Affiliate Files Intent to Sell $27.1M in Shares from Option Exercise
- NewAmsterdam Pharma Reports Reduced Net Loss, Strong Cash Position, and Advances Obicetrapib Towards EU Approval and Alzheimer's Trial
- NewAmsterdam Pharma Reports Strong 2025 Financials, Advances Obicetrapib Towards European Approval & Expands Pipeline
- NewAmsterdam Pharma Reports $729M Cash, Funds Operations Through PREVAIL CVOT Readout and US Launch
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$22.5M
Net Income
-$203.82M
Diluted EPS
-$1.72
Op. Cash Flow
-$147.78M
Free Cash Flow
-$148.03M
Operating Income
-$225.68M
Cash & Equivalents
$490M
Debt / Equity
0.00×
Net Margin
-9.06×
Shares Outstanding
114.4M sh
Source: 10-K · filed 2026-02-18 · accession 0001193125-26-056029
show_chartPrice Chart
Loading chart...
feed NAMS - Filings & News (Page 2)
NAMS
Feb 24, 2026, 4:22 PM EST
Price at Filing:
$36.01
Real-time Price:
$18.32
Change:
-$17.69 (-49%)
Market Cap:
$2.208B
NAMS
Feb 18, 2026, 7:00 AM EST
Price at Filing:
$34.74
Real-time Price:
$18.32
Change:
-$16.42 (-47%)
Market Cap:
$2.208B
NAMS
Feb 18, 2026, 7:00 AM EST
Price at Filing:
$35.35
Real-time Price:
$18.32
Change:
-$17.03 (-48%)
Market Cap:
$2.208B
NAMS
Jan 09, 2026, 8:00 AM EST
Price at Filing:
$35.73
Real-time Price:
$18.32
Change:
-$17.41 (-49%)
Market Cap:
$2.208B